MNG459
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.322
- E2F_TARGETS+0.289
- SPERMATOGENESIS+0.279
- G2M_CHECKPOINT+0.274
- PANCREAS_BETA_CELLS+0.266
- KRAS_SIGNALING_DN+0.242
- ANGIOGENESIS+0.013
- MYOGENESIS+0.009
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.024
- HEDGEHOG_SIGNALING-0.032
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.575
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.563
- TGF_BETA_SIGNALING-0.542
- INTERFERON_GAMMA_RESPONSE-0.532
- IL6_JAK_STAT3_SIGNALING-0.520
- OXIDATIVE_PHOSPHORYLATION-0.512
- ADIPOGENESIS-0.503
- PROTEIN_SECRETION-0.489
- HEME_METABOLISM-0.450
- APOPTOSIS-0.443
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_JVW2JJ39 | high-grade glioma | — | 0.949 |
| 2 | BS_JT82QGXF | medulloblastoma | — | 0.935 |
| 3 | BS_77317DY4 | medulloblastoma | — | 0.934 |
| 4 | BS_44A3ES23 | medulloblastoma | — | 0.930 |
| 5 | SRR650150 | — | — | 0.922 |
| 6 | SRR12202488 | — | — | 0.919 |
| 7 | MNG1288 | — | — | 0.916 |
| 8 | 266352 | EPN | EPN Tumor | 0.912 |
| 9 | BS_VPBMDMQX | medulloblastoma | — | 0.910 |
| 10 | BS_4E1G7E3G | ATRT | — | 0.908 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.322 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.289 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.279 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.274 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.266 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.242 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.013 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.009 | Inavolisib | — uncovered |